International Journal of Research and Scientific Innovation (IJRSI)
Current Perspectives on Analytical Method Validation of Empagliflozin: A Comprehensive Review
Published May 6, 2026 • Vol. 13, Issue 4, pp. 1427–1436Open Access
DOI: 10.51244/IJRSI.2026.1304000126
Abstract
Empagliflozin is an oral hypoglycemic drug belonging to the class of SGLT2 inhibitors. It acts on transporters in the proximal tubules of the kidneys to reduce blood glucose by promoting glucose excretion in the urine. This review examines various analytical method development strategies for Empagliflozin, with a focus on Quality by Design (QbD) approaches.
Keywords: Empagliflozin, Antidiabetic Drug, Analytical Method, QbD, ICH.
| Journal | International Journal of Research and Scientific Innovation (IJRSI) |
|---|---|
| ISSN | 2321-2705 |
| Volume / Issue | Volume 13, Issue 4 |
| Pages | 1427–1436 |
| Publication date | May 6, 2026 |
| DOI | 10.51244/IJRSI.2026.1304000126 |
| Publisher | RSIS International |
| License | Open Access |
How to cite this article
Lalit Bhoye, Dr. Uday A. Deokate, Vijay Lokhande, Muskan Mulla, Vaishnavi Punase, Vinod Kulkarni, & Govind Kokani (2026). Current Perspectives on Analytical Method Validation of Empagliflozin: A Comprehensive Review. International Journal of Research and Scientific Innovation (IJRSI), 13(4), 1427-1436. https://doi.org/10.51244/IJRSI.2026.1304000126
BibTeX
@article{Lalit2026,
title = {Current Perspectives on Analytical Method Validation of Empagliflozin: A Comprehensive Review},
author = {Lalit Bhoye and Dr. Uday A. Deokate and Vijay Lokhande and Muskan Mulla and Vaishnavi Punase and Vinod Kulkarni and Govind Kokani},
journal = {International Journal of Research and Scientific Innovation (IJRSI)},
volume = {13},
number = {4},
pages = {1427--1436},
year = {2026},
doi = {10.51244/IJRSI.2026.1304000126},
publisher = {RSIS International}
}